Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sabin strain inactivated poliovirus vaccine
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Sabin strain inactivated poliovirus vaccine (sIPV) is a trivalent, inactivated polio vaccine produced from attenuated Sabin strains of poliovirus types 1, 2, and 3 grown on Vero cells. The virus is harvested, purified, and inactivated with formaldehyde to ensure it cannot cause disease. sIPV induces protective antibodies against all three serotypes of poliovirus and is used for the prevention of poliomyelitis. It has demonstrated immunogenicity and safety profiles non-inferior to conventional wild-strain IPV (wIPV). Unlike oral polio vaccines containing live virus, sIPV carries no risk of vaccine-derived or vaccine-associated paralytic polio. It is primarily indicated for routine immunization of infants and children starting at two months old[1][2][5][6][7].
- Brand names
- EupolioEupolio InjSabin Inactivated Polio VaccineSabin-IPV
- Other names
- Sabin IPVPoliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
02
Targets
WPV3 (Poliovirus type 3 capsid protein)Poliovirus type 1 capsid protein
Beyond the preview
Go deeper on Sabin strain inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sabin strain inactivated poliovirus vaccine.